GlassScriptPhysician profile
Allie Nadelson
NPI 1942599618
$1,488.12
in general payments reported to CMS, 2019-2025
22 companies · $275 in 2025
The $275 reported for 2025 was less than what a typical Retina Specialist provider received nationally (typical 2025 total: $460).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $47.92 · 2020: $84.27 · 2021: $239 · 2022: $381 · 2023: $128 · 2024: $333 · 2025: $275.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $736.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $735.96 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Oyster Point Pharma, INC. | $250.20 | 2022-2025 | Tyrvaya, Ryzumvi |
| Sun Pharmaceutical Industries INC. | $168.99 | 2019-2021 | |
| Apellis Pharmaceuticals, INC. | $114.67 | 2022-2024 | Syfovre |
| Abbvie INC. | $107.24 | 2023-2024 | |
| Alcon Vision LLC | $95.64 | 2022-2025 | Rocklatan, Eysuvis, Total30 |
| Novartis Pharmaceuticals Corporation | $93.95 | 2019-2023 | |
| Sight Sciences, INC. | $75.36 | 2022 | |
| Bausch & Lomb Americas INC. | $60.46 | 2022-2024 | Miebo |
| Mallinckrodt Hospital Products INC. | $58.75 | 2022-2024 | Acthar |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $57.89 | 2019-2021 | |
| Biotissue Holdings INC. | $50.09 | 2022 | |
| Astellas Pharma US INC | $44.38 | 2025 | Izervay |
| Allergan, INC. | $42.87 | 2021 | |
| Dompe US, INC. | $39.86 | 2025 | Oxervate |
| Eyevance Pharmaceuticals LLC | $38.88 | 2021-2022 |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Johnson & Johnson Vision Care, INC. | $37.80 | 2021-2025 | |
| Tarsus Pharmaceuticals, INC. | $37.59 | 2024-2025 | Xdemvy |
| Regeneron Healthcare Solutions, INC. | $31.56 | 2025 | Eylea Hd |
| Amgen INC. | $24.20 | 2024 | Tepezza |
| Coopervision INC. | $21.76 | 2022 | |
| Kala Pharmaceuticals, INC. | $18.97 | 2022 | |
| Harrow Eye, LLC | $17.01 | 2025 | Triesence |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Allie Nadelson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.